TNF␣ levels are elevated in the marrows of patients with myelodysplastic syndrome (MDS) and are associated with high rates of apoptosis, which contributes to hematopoietic failure. We observed that exposure of human marrow stroma cell lines HS5 and HS27a to TNF␣ increases levels of IL-32 mRNA. IL-32, in turn, induces TNF␣. Marrow stroma from patients with MDS expressed 14-to 17-fold higher levels of IL-32 mRNA than healthy controls. In contrast, cells from patients with chronic myelomonocytic leukemia (CMML) expressed only one tenth the level of IL-32 measured in healthy controls. Human KG1a leukemia cells underwent apoptosis when cocultured with HS5 stromal cells, but knockdown of IL-32 in the stromal cells by using siRNA abrogated apoptosis in the leukemia cells. IL-32 knockdown cells also showed dysregulation of VEGF and other cytokines. Furthermore, CD56 ؉ natural killer cells from patients with MDS and CMML expressed IL-32 at lower levels than controls and exhibited reduced cytotoxic activity, which was unaffected by IL-2 treatment. We propose that IL-32 is a marrow stromal marker that distinguishes patients with MDS and CMML. Furthermore, IL-32 appears to contribute to the pathophysiology of MDS and may be a therapeutic target. marrow stroma ͉ TNF␣
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Molldrem et al. (10) showed that a proportion of patients with MDS harbored autoreactive T lymphocytes, which provided a source of TNF␣. Macrophages from MDS marrow also generate increased amounts of TNF␣ spontaneously and after stimulation (11) . However, whereas TNF␣ is a recognized factor in the dysregulation of hematopoiesis, the proapoptotic property of TNF␣ alone cannot satisfactorily explain the entire spectrum of MDS.
Here, we observed that the leukemia-derived cell line KG1a, which is resistant to TNF␣-mediated apoptosis, became sensitive to TNF␣-induced apoptosis when cocultured with the human marrow-derived stroma cell lines HS5 or HS27a. Apoptosis was contact-dependent, consistent with a model that TNF␣-modified signals in the microenvironment affected the leukemia (or MDS) clone. Microarray gene expression analysis of HS5 and HS27a cells revealed prominent induction of IL-32 by TNF␣ (12) . Because IL-32 appears to contribute to inflammatory and autoimmune diseases (13) (14) (15) (16) and induces TNF␣ and apoptosis (17) , we hypothesized that IL-32 and TNF␣ participate in an autoamplification loop in MDS that promotes apoptosis. Therefore, the levels of TNF␣, IL-32, or both should be lower in patients in whom proliferation, rather than apoptosis, was the dominant feature. One such disorder is chronic myelomonocytic leukemia (CMML), originally categorized as MDS (18) , but recently reclassified by the World Health Organization as a distinct entity (19) . Indeed, ex vivo studies showed low TNF␣ levels in patients with CMML (20) (21) (22) .
Similar to other cytokines, IL-32 may exert its functions even in a membrane-bound form. Also, IL-32 is released from cells upon apoptosis, thus allowing for the induction of TNF␣ (and apoptosis) in other target cells (23) . Although we realize that cytokine levels in mononuclear cells may not reflect levels in marrow stroma, we determined IL-32 expression in marrow and peripheral blood cells from patients with MDS and CMML, in comparison with cells from healthy control subjects, and we began to characterize its functional relevance.
Results

IL-32 Expression in Human Marrow
Stroma. Human marrow stroma cell lines. Preliminary studies indicated that exposure of the human marrow stroma cell lines HS5 and HS27a to TNF␣ increased the expression of several genes, including IL-32 (Fig. 1A) . We confirmed those findings by using quantitative RT-PCR for RNA (Fig. 1B) and Western blot analysis for the IL-32 protein (Fig. 1C) . Because others had shown that IL-32 induces the expression of TNF␣ (17) , the present observations suggested the possibility of an autoamplification loop of TNF␣ and IL-32. Primary marrow stroma cells. Primary adherent stroma cells were obtained from human marrows by depleting CD45 ϩ cells (including macrophages) (see Materials and Methods). The purity was Ն95% as determined by the absence of staining for CD14, CD34, CD11b, and CD45. Adherent cells derived from the marrows of 13 patients with untreated MDS expressed significantly higher levels of steady-state IL-32 mRNA, compared with cells from six healthy subjects (P ϭ 0.014) (Fig. 2) . In contrast, adherent cells derived from six patients with CMML exhibited a significantly lower constitutive expression of IL-32 (P ϭ 0.01), and patients with CMML also were shown to express low levels of TNF␣ (21, 24) .
Coculture with Stroma Cells Renders KG1a Cells Sensitive to TNF␣-
Induced Apoptosis. The leukemia cell line KG1a is nearly completely resistant to TNF␣-induced apoptosis in both the absence and presence of stroma (25) . However, when TNF␣ was added to contact cocultures of KG1a and stroma, apoptosis of KG1a cells increased significantly, and KG1a cells detached from the stroma. KG1a cells that remained adherent to stroma showed little or no apoptosis.
We speculated that the induction of apoptosis was related to the up-regulation of IL-32 (or other proapoptotic factors) in HS5 cells after TNF␣ exposure. To determine the role of IL-32, we reduced the constitutive level of IL-32 expression in HS5 cells by using siRNA and performed the same coculture experiments. As shown in Fig. 3A (HS5KOIL32) , a lower expression of IL-32 was accomplished. As illustrated in Fig. 3B , KG1a cells cocultured with HS5KOIL32 cells failed to undergo apoptosis even in the presence of exogenous TNF␣. Identical results were obtained with HS27a [supporting information (SI) Fig. 7 ]. We interpreted these data as due to a biologically active form of IL-32, which is likely membrane-bound on stroma cells (15) , and the induction of apoptosis in KG1a cells.
Interactions of TNF␣, IL-32, and VEGF.
Others have suggested that the inhibitory effect of VEGF on hematopoiesis was mediated by the local generation of TNF␣ (26) and that neutralization of VEGF reduced the transcription of TNF␣ (6) . We observed that, after overnight culture of HS5 and HS5KOIL32 cells, concentrations of VEGF were significantly lower in the supernatant of HS5KOIL32 cells (Fig. 4A) . Concentrations of TNF␣ were below the level of assay sensitivity. In addition, a broad array of 36 cytokines, using protein dot blots, showed significant reduction Fig. 2 . Expression of IL-32 in primary marrow-derived stroma cells from untreated patients with CMML (n ϭ 6) or MDS (n ϭ 13) and healthy control subjects (n ϭ 6). mRNA levels were determined by quantitative RT-PCR. P values are in comparison with healthy subjects. IL-32 levels were significantly lower in patients with CMML (P ϭ 0.01) and higher in patients with MDS (P ϭ 0.014). of RANTES, MCP-1, IL-6, IL-8, G-CSF, sICAM-1, MIF, and Serpine 1 in HS5KOIL32 supernatant (VEGF was not represented) (Fig. 4B) .
IL-32 Expression in Natural Killer (NK) Cells. The cDNA of IL-32 was originally cloned from NK cells (27) . NK cells were of interest to us because abnormal NK function has been reported in patients with MDS (27) . Thus, in a final set of experiments, we determined steady-state levels of IL-32 mRNA in CD56 ϩ NK cells from patients with MDS or CMML (Fig. 5A) . The baseline expression of IL-32 in CD56 ϩ cells from peripheral blood of patients with CMML was lower than in CD56 ϩ cells from healthy donors (P ϭ 0.001). Conversely, in patients with MDS, the baseline expression of IL-32 tended to be higher than in healthy controls, although the difference did not reach statistical significance (P ϭ 0.48).
In other cell populations such as CD34 ϩ cells and more differentiated granulocytes, the patterns of expression were less consistent (data not shown). Fig. 5B summarizes data on cytotoxicity of CD56 ϩ NK cells against K562 target cells. CD56 ϩ cells from healthy donors exhibited the expected cytotoxicity, which increased with higher effector/target ratios. In contrast, no increase was seen with CD56 ϩ cells from MDS or CMML patients (P ϭ 0.001). A slight increase in NK cytotoxicity in MDS-derived CD56 ϩ cells did occur at higher effector/target ratios after activation with IL-2. However, at identical ratios, cytotoxicity consistently lagged behind that of cells from healthy donors. Despite differences in baseline IL-32 expression, CD56 ϩ cells from the peripheral blood of patients with CMML showed cytotoxicity comparable to that of CD56 ϩ cells from patients with MDS, suggesting that factors in addition to IL-32 were involved. healthy donors and patients with MDS or CMML. Because we combined MDS (higher IL-32 at baseline) and CMML (lower IL-32 at baseline) patients, the average level of expression was similar to that in healthy donors in unstimulated samples. However, after IL-2 stimulation, in contrast to healthy donors, no up-regulation of IL-32 occurred in either MDS or CMML cells. Further, TNF␣ secretion by CD56 ϩ cells from patients with MDS or CMML was consistently lower than in cells from healthy controls both without (P ϭ 0.03) and with (P ϭ 0.01) IL-2 stimulation (Fig. 6) . Again, because baseline IL-32 levels differed between MDS and CMML cells, factors in addition to IL-32 are likely involved in NK dysfunction in these patients.
IL-32 Expression and NK Cell Function.
Discussion
The present study revealed significant dysregulation of IL-32 expression in marrow and peripheral blood cells from patients with MDS and CMML.
In comparison with healthy controls, the constitutive expression of IL-32 mRNA was higher in primary stroma cells from patients with MDS and significantly reduced in patients with CMML. A similar pattern was observed in peripheral blood CD56 ϩ NK cells (i.e., the cells from which the IL-32 cDNA was cloned originally) (27) . Because recent data indicate that the marrow microenvironment contributes to the pathophysiology of MDS and because NK function is abnormal in MDS (6, 12, 28), we were interested in determining IL-32's possible role in these disorders.
We observed previously that TNF␣ protein levels were higher in the marrow of patients with MDS, and we showed that neutralization of TNF␣ activity enhanced hematopoiesis (4). The gene expression profiling of the human stroma lines HS5 and HS27a revealed a striking up-regulation of IL-32 in response to TNF␣ (12) . Because IL-32 had been shown to induce TNF␣ (17), we hypothesized that an autoamplification loop of TNF␣ and IL-32 contributed to the dysregulation of apoptosis in MDS marrow. If so, then the marrow of patients with proliferative disorders, such as CMML, with low rates of apoptosis, should, as observed here, show low levels of TNF␣, IL-32, or both.
The role of TNF␣ in the pathophysiology of MDS has been characterized (4, 29) , whereas the role of IL-32 is unknown. KG1a cells, used as a model (no stable MDS cell lines are available), were nearly completely resistant to TNF␣-induced apoptosis (25) . However, when exposed to TNF␣ in cocultures with HS5 stroma, KG1a cells underwent apoptosis. When the same experiment was carried out with HS5KOIL32 cells, apoptosis in KG1a cells was significantly reduced. Thus, IL-32 in and on HS5 cells appears to deliver proapoptotic signals to KG1a cells.
These results are not in conflict with the concept that stroma contact protects leukemic cells (30, 31) . KG1a cells became apoptotic only after contact with stroma in the presence of TNF␣. Our data are in agreement with a report by Goda et al.(23) , who showed that up-regulation of IL-32 induced apoptosis, whereas down-regulation resulted in proliferation, a pattern similar to that observed in stroma cells from patients with MDS (high levels of IL-32 and apoptosis) and CMML (low levels of IL-32 and no apoptosis), respectively. The present data indicate that the final outcome of cell death or survival depended on the milieu in which stroma interactions occurred.
To further define the mechanism that resulted in lower rates of apoptosis in KG1a cells cocultured with HS5KOIL32 cells, we determined patterns of other cytokines that are dysregulated in MDS marrow (3, 22) . For example, Bellami et al. (6) suggested that the neutralization of VEGF led to the suppression of TNF␣ transcription. Such a model is supported by our data, which show that silencing of IL-32 in stroma resulted in a significant decrease in the secretion of VEGF.
In primary stroma (and hematopoietic) cells from patients with CMML, lower steady-state levels of IL-32 mRNA, as expected, were associated with lower levels of TNF␣ and VEGF production. Molnar et al. (21) also showed lower levels of TNF␣ and VEGF in the marrow of CMML patients, compared with healthy controls and patients with MDS, consistent with the hypothesis of an autoamplification loop of TNF␣ and IL-32.
IL-32 was initially reported as a cDNA without known function(s) in IL-2-activated NK and T cells (27) , both cell types involved in the pathophysiology of MDS (10, 28) . Immunosuppressive therapy (e.g., with antithymocyte globulin) or immunomodulation (e.g., with thalidomide, which interferes with T and NK cell function) have shown therapeutic benefits in some patients with MDS, but not with CMML (21, 24). Kiladjian et al. (28) reported recently that CD56 ϩ NK cells from patients with MDS were quantitatively normal, but functionally abnormal. The present data support those findings and indicate that NK dysfunction was associated with the dysregulation of IL-32 and impaired activation in response to IL-2. However, whereas constitutive expression of IL-32 was low in CMML, it was increased in patients with MDS, compared with healthy controls. Thus, additional factors are likely to be involved in NK dysfunction in these patients. These data offer insights, but also add to the complex picture of the pathophysiology of MDS. The in vivo relevance of IL-32 dysregulation for MDS remains to be proven. It may provide an important link between the immune system [both innate (NK) and adaptive (T cells)] and dysregulated hematopoiesis (10, 28) , as well as between hematopoietic cells and the microenvironment. Intriguing in this context are observations by Roth et al. (32) , who showed that phenotypic and functional maturation of NK cells required intimate interactions with stroma cells.
In summary, the current study provides evidence for a role of IL-32 in the pathophysiology of clonal myeloid diseases and provides objective data for a distinction between CMML and MDS, supporting the reclassification of CMML as a distinct disorder (19) . Conceivably, IL-32 (or components in the signaling pathway) could serve as therapeutic targets for patients with MDS and MPD.
Materials and Methods
Cell Lines, Cultures, and Reagents. HS5 and HS27a are human stroma cell lines derived from the marrow of a healthy volunteer (33) . The human myeloid leukemia cell line, KG1a, was obtained from D. Banker (Fred Hutchinson Cancer Research Center) (34) . TNF␣ was purchased from PeproTech. IL-2 was obtained from Invitrogen.
Cell lines were maintained and processed for use in experiments as described (25) . Primary cells from marrow aspirates and peripheral blood from healthy volunteers and patients with MDS or CMML were obtained, and Fig. 6 . Secretion of TNF␣ by CD56 ϩ NK cells from healthy subjects (n ϭ 8) and patients with MDS or CMML (MDS; n ϭ 16). TNF␣ was measured by ELISA at baseline (control) and 24 h after 500 units/ml IL-2. Shown is the mean Ϯ SD (pg/ml). Although there was considerable variation in cells from healthy donors, little or no TNF␣ was secreted from MDS-derived cells even after activation by IL-2.
